Corcept Therapeutics reported $98.72M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Alaunos Therapeutics USD 124K 230K Jun/2026
ANI Pharmaceuticals USD 420.76M 60.55M Sep/2026
Ardelyx USD 46.32M 50.87M Sep/2026
Aurora Cannabis CAD 69.31M 4.62M Jun/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Canopy Growth CAD 336.62M 28.06M Jun/2026
Corcept Therapeutics USD 98.72M 12.32M Sep/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Merck USD 9.55B 2.7B Sep/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Novartis USD 8.87B 1.25B Sep/2026
Novartis USD 8.87B 1.99B Sep/2026
Omeros USD 1.9M 2.36M Jun/2025
Pfizer USD 1.82B 848M Sep/2026
Supernus Pharmaceuticals USD 175.88M 4.07M Sep/2026
TG Therapeutics USD 429.38M 182.88M Sep/2026